Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective * Weight \>= 40 kg * Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 * Life expectancy \> 3 months * Absolute neutrophil count (ANC) \>= l500/ul * Hemoglobin \>= 9g/dL * Platelets \>= 100,000/ ul * Total bilirubin \< 1.5 x upper limit of normal * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvate transaminase (SGPT) \< 2.5 x upper limit of normal for patients without liver metastases OR SGOT and SGPT \< 5 x upper limit of normal for patients with liver metastases * Measurable or non-measurable disease will be allowed * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation, up until 30 days after final study treatment; should a woman become pregnant or suspect that she is pregnant while participating in this study, she should inform her treating physician immediately * Patients taking substrates, inhibitors, or inducers of cytochrome P450 (CYP)3A4 should be encouraged to switch to alternative drugs whenever possible, given the potential for drug-drug interactions with sirolimus * Signed informed consent Exclusion Criteria: * Prior treatment with a mammalian target of rapamycin (mTO…